| 07/10/2024 15:30 |
Corporate Governance Report 2024/7/10 |
| 07/09/2024 08:30 |
Takeda Completed Issuance and Disposal of Shares under the LTIP for Company Group Employees Outside of Japan with Partial Forfeiture |
| 07/02/2024 00:30 |
2024 ANNUAL INTEGRATED REPORT |
| 06/26/2024 17:00 |
Annual Securities Report From April 1, 2023 to March 31, 2024 (The 147th Fiscal Year) |
| 06/26/2024 16:00 |
Takeda Announces New Assignments of Directors |
| 06/17/2024 19:45 |
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome |
| 06/11/2024 16:00 |
Issuance of New Shares and Disposal of Treasury Shares underthe Long-Term Incentive Plan for Company Group Employees Outside of Japan |
| 06/11/2024 08:00 |
Partial Correction to the Notice of Convocation of the 148th Ordinary General Meeting of Shareholders |
| 06/08/2024 08:00 |
Statement From the Chair of the Board of Takeda,in Response to ISS's Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholder |
| 06/07/2024 11:00 |
Notice Regarding Pricing of JPY Hybrid Bonds |
| 06/03/2024 19:45 |
TAK-861 Ph2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in NT1 |
| 06/03/2024 16:00 |
Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan |
| 05/30/2024 08:00 |
TAKEDA'S EXECUTIVE COMPENSATION OVERVIEW |
| 05/30/2024 08:00 |
Message from Christophe Weber, President & CEO |
| 05/30/2024 08:00 |
Other items which are provided electronically for the 148th Ordinary General Meeting of Shareholders |
| 05/30/2024 08:00 |
Notice of Convocation of the 148th Ordinary General Meeting of Shareholders and Meeting Materials |
| 05/21/2024 15:30 |
(Correction) Partial Correction of the Summary of Financial Statements for the Fiscal Year Ended March 31, 2024 (IFRS, Consolidated) |
| 05/09/2024 16:00 |
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2024 |
| 05/09/2024 15:15 |
Takeda Announces With Sadness the Passing of Board Member Olivier Bohuon |
| 05/09/2024 15:00 |
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement |
| 05/09/2024 15:00 |
Difference between Forecast and Actual Results for the Fiscal Year Ended March 2024 |
| 05/09/2024 15:00 |
Summary of Financial Statements for the Fiscal Year Ended March 31, 2024 (IFRS, Consolidated) |
| 04/15/2024 13:00 |
Notice Regarding Issuance of JPY Hybrid Bonds |
| 03/27/2024 08:00 |
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting |
| 02/09/2024 08:00 |
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024 |
| 02/02/2024 16:00 |
Quarterly Securities Report (The third quarter of 147th Business Term) for The Nine-month Period and Three-month Quarter Ended December 31, 2023 |
| 02/01/2024 15:30 |
Takeda Announces Chief Financial Officer Succession |
| 02/01/2024 15:00 |
Summary of Financial Statements for the Nine-month Period Ended December 31, 2023 (IFRS, Consolidated) |
| 01/15/2024 16:00 |
Announcement of a company split (simplified absorption-type company split/short-form company split) with a wholly-owned subsidiary |
| 12/14/2023 16:00 |
Corporate Governance Report 2023/12/14 |
| 11/30/2023 17:00 |
The 147th (interim period) Business Report |
| 11/10/2023 08:45 |
Takeda's ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of cTTP |
| 10/30/2023 16:00 |
Quarterly Securities Report (The second quarter of 147th Business Term) for The Six-month Period and Three-month Quarter Ended September 30, 2023 |
| 10/26/2023 15:00 |
Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS) |
| 10/26/2023 15:00 |
Summary of Financial Statements for the Six-month Period Ended September 30, 2023 (IFRS, Consolidated) |
| 10/18/2023 08:30 |
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire |
| 10/02/2023 15:00 |
Takeda Announces Amendment of Compensation Recoupment Policy |
| 09/28/2023 08:45 |
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis |
| 09/11/2023 19:45 |
Positive Topline Results from Ph2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis |
| 08/01/2023 16:00 |
Quarterly Securities Report (The first quarter of 147th Business Term) for The Three-month Period Ended June 30, 2023 |
| 07/27/2023 15:00 |
Summary of Financial Statements for the Three-month Period Ended June 30, 2023 (IFRS, Consolidated) |
